Forkhead box protein M1 mRNA (FOXM1)

Forkhead box protein M1 (FOXM1) is a master transcription factor of the Forkhead family that plays a pivotal role in the regulation of the mammalian cell cycle, specifically governing the transition from G1 to S phase and the progression into mitosis. It orchestrates the expression of a vast network of genes involved in DNA replication, chromosome segregation, and genomic stability. While essential for normal embryonic development and adult tissue repair, FOXM1 is aberrantly overexpressed in nearly all human solid tumors, where it acts as a potent oncogene driving cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, and resistance to chemotherapy. Targeting FOXM1 mRNA specifically, through modalities such as small interfering RNA (siRNA) or antisense oligonucleotides (ASOs), offers a strategy to deplete all protein isoforms and suppress its multifaceted oncogenic functions. Although no FOXM1-targeted therapies are currently FDA-approved, several small molecules and RNA-based inhibitors are under preclinical investigation, showing promise in sensitizing cancer cells to existing treatments and inhibiting tumor growth.

Other names

HFH-11MPP2WININS-1FKHL16TRIDENTMPHOSPH2TGT3PIG29Forkhead box M1

Targeting FOXM1 mRNA typically involves the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASOs) to induce mRNA degradation via the RNA interference (RNAi) pathway or RNase H-mediated cleavage, thereby preventing the translation of the FOXM1 protein. Additionally, small molecule inhibitors can indirectly reduce mRNA levels by disrupting positive feedback loops or inhibiting upstream transcriptional activators.